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Thousands of bacterial phylotypes colonise the human body and the host response to this bacterial challenge
greatly influences our state of health or disease. The concept of infectogenomics highlights the importance of
host genetic factors in determining the composition of human microbial biofilms and the response to this
microbial challenge. We hereby introduce the term ‘genetic dysbiosis’ to highlight the role of human genetic
variants affecting microbial recognition and host response in creating an environment conducive to changes
in the normal microbiota. Such changes can, in turn, predispose to, and influence, diseases such as: cancer,
inflammatory bowel disease, rheumatoid arthritis, psoriasis, bacterial vaginosis and periodontitis. This review
presents the state of the evidence on host genetic factors affecting dysbiosis and microbial misrecognition (i.e.
an aberrant response to the normal microbiota) and highlights the need for further research in this area.
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D
uring their evolution, vertebrates and their colo-
nising microbes have evolved mechanisms to live
in symbiosis with each other. One of the major
paradigm shifts in modern biomedicine is the realisation
of how heavily vertebrates are colonised by bacteria (1). It
is now recognised that humans are supra-organisms (2)
with 90% of the cells in the human body being bacterial
(3), termed the normal bacterial microbiota. It is esti-
mated that in the human gut, the microbiome outnumbers
the human genome by 150-fold (4). Culture-dependent
methods have identified several hundred bacterial species
colonising the skin and the mucosal surfaces of the
oral cavity, airways, gut and genitourinary tract (5). In
these locations, bacteria flourish from the first moments
after birth and adhere to each other forming aggregates
termed biofilms. Culture-independent methods involving
cloning and 16S rRNA gene sequencing (6) or cloning-
independent 16S rRNA gene analysis using massively
parallel next generation DNA sequencing (7) have in-
creased the numbers of bacterial phylotypes recognised as
colonising humans into the thousands (8). However, only
a small proportion of these colonising bacteria can be
cultivated in the laboratory and have ever been studied (5).
The differences in bacterial colonisation between indivi-
duals in these studies lend strength to the idea that each
individual human will, as a rule, have a subset of his or
her own colonising bacteria in different body habitats,
which may impact on the individuals state of health and
disease (9).
Microbial diseases
The traditional meaning of ‘microbial disease’ includes
infections such as smallpox, tuberculosis or AIDS, caused
by colonisation and infection by a specific pathogenic
microbe, usually transmitted between individuals. Some
microbes or even microbial strains may indeed be res-
ponsible for more than one disease state, an example being
E. coli, associated with gastro-intestinal and urinary in-
fections as well as meningitis. However, microbial-based
disease extends well beyond this meaning as many major
idiopathic diseases have a history of research involving the
hypothesis that one or other infectious agent, bacterium,
bacterial L-form, virus and so forth, is the cause of the
disease. An example of this is rheumatoid arthritis, which
was thought to be caused by a wide variety of micro-
organisms (10). Notably, there is now increasing interest
in the relationship between rheumatoid arthritis and
periodontitis with a novel hypothesis that the peptidylar-
ginine deiminase of the oral bacterium Porphyromonas
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gingivalis can generate citrullinated proteins which are
highly immunogenic and may function as key auto-
antigens in rheumatoid arthritis (11, 12). This raises the
question as to whether other enzymes of the microbiota
can redirect the attention of immunity to produce auto-
immune outcomes or, indeed, unknown consequences as a
result of protein decoration.
Over the past 20 years there has been a suggestion
that bacteria and viruses play a role in the process of
atherogenesis (13). Cancer is also a good example of a
complex disease process in which viruses certainly par-
ticipate (14) and in which growing evidence exists for
bacterial involvement in its pathogenesis (15, 16). It has
been estimated that 16% of cancers are initiated by specific
microbial factors (17), a clear example being Helicobacter
pylori, which is responsible for gastric adenocarcinoma.
Microbial infections have been shown to lead to
cancer either by direct action of viral oncogenes such as
for human papillomaviruses (HPV) and cervical cancer
(18) or by indirect action such as promotion of chronic
inflammation (19), DNA damage (20) and production of
bioactive carcinogenic metabolites (21). A key mechanism
through which microbes can promote dysplastic changes
is illustrated by the up-regulation of inflammatory path-
ways, such as nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB) pathway and pro-inflammatory
cytokines by the bacterial cytolethal distending toxin of
Helicobacter hepaticus in H. hepaticus-infected mouse
livers (22).
In addition to these diseases, recent research has
identified a group of conditions probably resulting from
dysbiosis, or alternatively referred to as originating from
a misrecognition or aberrant response to the normal
microbiota, including inflammatory bowel disease (IBD),
psoriasis (PS), bacterial vaginosis (BV) and periodontal
diseases (PD) (2326). These four diseases seem to cluster
together from an epidemiological, pathogenic, genetic
and microbial standpoint, with similarities between them
being recently reported (2736).
Genetic dysbiosis
A common feature of the diseases described above is that
they are not, like common infections, caused by indivi-
dual bacterial species. Rather, they appear to be the result
of a dysbiosis, which is a change in the normal micro-
biota, or of misrecognition of the normal microbiota
within different body environments. A sensible hypothesis
is that genetic defects in the recognition and response
pathways that the host uses to identify microbial patho-
gens predispose to either altered microbial colonisation
or to the misrecognition of normal microbiota that lead
to these diseases. We could refer to ‘genetic dysbiosis’
to define this mechanism. This underpins the concept of
infectogenomics (37), for which two distinct pathways
have been recognised:
Bacterial recognition
Mammals have a very wide variety of pattern-recognition
receptors (PRRs), which recognise evolutionarily-conserved
constituents of microbes called pathogen-associated mo-
lecular patterns (PAMPs) (38). These include the toll-
like receptors (TLRs), NOD-like receptors (NLRs),
RIG-I-like receptors (RLRs), C-type-lectin like receptors
(CLRs), scavenger receptors (SCs), innate DNA receptor
proteins termed AIM2-like receptors (ALRs), members of
the complement pathways and peptidoglycan-recognition
proteins (PRPs). In addition to these proteins, which are
mainly cell-bound, there are also a range of soluble PRRs
including collectins, ficolins, pentraxins, galectins, sCD
(cluster of differentiation) 14 and natural IgM (immuno-
globulin M). Each of these families of proteins contains
multiple members (3941). In addition, these various
receptor-based and soluble PRRs generally interact
with various accessory proteins to allow for selective cell
signalling. It is consequent upon binding of bacteria,
or other microbes (or constituents of these microbes), to
these PRRs that the target cell generates pro- and/or anti-
inflammatory proteins such as cytokines. Mutations in
the promoter regions and coding segments of the indivi-
dual PRR genes may result in either altered expression
of PRRs or differences in the ability to recognise the
microbial constituents that they bind to respectively.
In addition to the influence of PRR production and
PRR kinetics of binding, changes in the interaction
between the PRR and obligatory accessory proteins
may be a factor in this ‘binding/recognition’ process.
Initial evidence has recently been produced for the effect
of microbial recognition genes on microbial presence
in periodontal (42) and vaginal biofilms (43, 44). In these
conditions, a proposed hypothesis is that genetic fac-
tors which may determine an aberrant epithelial barrier
(through defects in PRRs and innate immune signalling
pathways) may induce microbial shifts and an inflamma-
tory cascade which can give rise to chronic diseases and
even cancer (27).
Bacterial proliferation
Several human surfaces in contact with the outside
environment lend themselves to be colonised by a complex
structure consisting of several layers of bacteria and
other microorganisms, called a biofilm. As well as affecting
bacterial recognition, common human genetic variants are
likely to be responsible for creating a favourable environ-
ment for fostering the growth of specific pathogenic
bacteria within biofilms. The hypothesis is that genetic
variants predisposing to an excessive inflammatory re-
sponse create a favourable environment for the selective
growth of specific bacteria within the human biofilms,
which, due to specific characteristics in their metabo-
lism, grow well in more inflamed environments. Initial
evidence in periodontitis suggests that cytokine gene
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polymorphisms may select and favour the growth of
certain components of the sub-gingival biofilm (42, 45).
Similarly to periodontitis, other human diseases might
be affected by the overgrowth of certain components of
the biofilms upon stimulation by a more or less ‘inflamed’
environment (37). It has been hypothesized that mutations
in genes involved in immune regulatory mechanisms or
pro-inflammatory pathways could lead to unrestrained
inflammation in the intestine and that inflammation can
influence the composition of the microbiota, skewing it
in favour of pathological microorganisms (46). However,
doubts still exist on whether the inflammatory deregu-
lation is the cause, or actually the consequence, of a
microbial shift in such cases.
Genetic dysbiosis in IBD
IBD describes two conditions, namely Crohn’s disease
(CD), usually affecting the terminal ileum (but which can
affect anywhere in the GI tract), and ulcerative colitis
(UC), which is a chronic non-transmural inflammatory
condition localised in the colon. Both are characterised by
an intermittent course with symptoms including abdom-
inal pain, diarrhoea and vomiting. IBDs result from the
interaction between genetic susceptibility and environ-
mental factors. Although there is no definition for ‘healthy’
microbiota, several conditions including IBD along with
obesity and metabolic syndrome are associated with
changes in intestinal microbial biofilms (47). A metage-
nomic case-control study revealed significant differences
in microbial compositions of a subset of IBD patients
compared with healthy controls (48). A process of dysbio-
sis, for example related to childhood exposure to anti-
biotics, is implicated in the pathogenesis of IBD (49, 50).
Whilst there is evidence that gut microbiota can modulate
the expression of genes involved in different intestinal
activities (51) and that some resident bacteria have the
potential to cause disease, no bacterium has so far been
singled out as causative for IBD (34). Bacterial type VI
secretion systems (T6SSs) of H. hepaticus, a gram-negative
bacterium of the intestinal microbiota, have been shown
to direct an anti-inflammatory gene expression profile
in intestinal epithelial cells, thus limiting colonization
and intestinal inflammation. This is in contrast with the
aforementioned effect of promotion of dysplastic changes
by this bacterium in mice (22) and could be explained
with the concept that H. hepaticus acts as an intestinal
pathobiont, in other words a symbiont able to promote
pathology only when certain host genetic or environ-
mental conditions are altered (52). This example illustrates
the importance of intestinal bacteriahost interactions
and suggests that disruption of this hostmicrobial
balance could contribute to human disorders such as IBD
and colon cancer (52). Genome-wide association studies
(GWAS) have now made considerable progress in the
identification of genetic variants predisposing to IBD.
There is evidence for a role of genetic variants in genes
coding for bacterial recognition receptors in disease
pathology. The best-known and most researched gene
associated with IBD is NOD2, which codes for an intra-
cellular pattern-recognition receptor, able to recognise
molecules containing bacterial muramyl dipeptide (53).
Genetic variants in this gene are associated with a higher
risk of developing CD (54), owing to the pleiotropic role of
this receptor in bacterial recognition and in the inflamma-
tory response. In general, genes linked to epithelial barrier
function seem to be specifically associated with UC, while
bacterial recognition genes such as NOD2 and autophagy
genes seem to be associated with CD (50). These findings
are consistent with the involvement of the more superfi-
cial epithelial layers in UC and the deeper trans-mural
inflammation of CD (supposedly caused by defects in
cellular innate immunity and bacterial handling in the
deeper layers of the lamina propria and beyond) (50).
Therefore, while it is now clear that both genetic suscept-
ibility and dysbiosis predispose to IBD, further work is
required to understand the effect of genetic variants in
determining such dysbiosis (55, 56).
Initial evidence for a role of genetic variants in
conferring greater vulnerability to inflammation and dys-
biosis in CD comes from an experimental ileal inflam-
mation model in mice (57). In this model, when a
CD susceptible genotype (NOD2 mutations) was super-
imposed on Toxoplasma gondii-induced ileitis, an increase
in inflammation and dysbiosis was noticed (measured by
pyrosequencing as a shift from mainly gram-positive to
gram-negative bacteria, associated with invasive E. coli).
The authors proposed that inflammation drives a pro-
gressive decrease in the microbial diversity leading to
perturbations in the microenvironment such as increased
availability of substrates for growth of gram-negative
bacteria (e.g. iron and serum, dead or dying cells) and
loss of niche and substrates for gram-positive flora (e.g.
mucus, goblet cells). Genetic susceptibility could poten-
tially impact the threshold for dysbiosis and the indi-
vidual ability to resolve the self-perpetuating cycle of
dysbiosis and inflammation generated by an acute trigger
(57). Admittedly, further research in humans is needed
to substantiate the ‘dysbiosis’ evidence in IBD, mainly
derived from animal models. However, even if IBD-
associated dysbiosis was not an initiator of disease,
dysbiosis may be important in perpetuating the disease (4).
Genetic dysbiosis in PS
PS is a chronic condition characterised by the appearance
of inflammatory, erythematous scaly lesions on the skin,
linked to the development of arthritis. The most common
form of PS is ‘plaque PS’, while other forms include
guttate, pustular, erythrodermic and inverse (or flexural)
PS (58). PS research has a long history of associations
with bacterial infection/colonisation. Over 50 years ago,
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it was noted that two thirds of patients with the variant
guttate psoriasis (GP) had a preceding sore throat and
serological evidence of a streptococcal infection (59). This
was then confirmed by the isolation of beta haemolytic
streptococci [BHS] from the throats of patients with GP
(60). Furthermore, guttate flares in chronic plaque PS are
associated with streptococcal pharyngitis (61). Micro-
biological analysis of psoriatic skin report conflicting
evidence on types of bacteria associated with the lesions:
16S rRNA gene analysis using swabbing of the skin
to recover bacteria, has revealed differences in bacterial
colonisation compared to healthy skin, with an increase
in Firmicutes and a decrease in Actinobacteria (25).
Similarly, in a study on biopsy specimens (62) using
massive parallel sequencing of the 16S rRNA genes
revealed differences in microbial colonization between
psoriatic and healthy skin. Biopsies give a more reliable
picture of the skin microbiome as it has recently been
shown that bacteria are present throughout the skin (63)
and thus swabs are not sufficient to study the microbiome
of the skin. Psoriatic lesions are highly infiltrated with
immune cells including CD3 T cells and CD11c
dendritic cells (DCs) (64, 65). Family history and
increased prevalence in twins have directed PS research
towards the search for a genetic susceptibility locus (66)
and the PSORS1 (PS susceptibility 1) locus was found
on chromosome 6p21.3 (67, 68). In a recent GWAS
study (69), 36 genetic loci were found to be associated
with PS. The majority of these loci involved candidate
genes governing the innate immune system including
NFkB activation and interleukin (IL)-23 signalling.
Genes affecting adaptive immune response and epidermal
barrier function have also been suspected to have a role in
the pathogenesis of PS (70). Thus it is possible that PS is
due to dysbiosis of bacteria colonising the skin (36) and
that genetic variants predispose to this dysbiosis. How-
ever, further research in this field is needed to substanti-
ate this hypothesis.
Genetic dysbiosis in periodontitis
PD are inflammatory diseases of the gingivae (gums)
associated with destruction of the supporting tissues of
the teeth (periodontal ligament and alveolar bone) and
early loss of the dentition (71). Periodontitis is due to an
aberrant response to members of the sub-gingival micro-
biota (72) and, together with its non-destructive partner
condition, gingivitis, is one of the most prevalent chronic
inflammatory conditions of humanity. Mild to moderate
periodontitis affects 1357% of the population according
to different studies, with severe forms affecting up to
25% of individuals (73). A recent survey in an US adult
population of 3,742 individuals revealed a prevalence
of 47% for periodontitis (74). Periodontitis has a multi-
factorial aetiology, where the combination of common
genetic variants alters the response to the sub-gingival
microbiota, predisposing to disease onset and pro-
gression (72). Periodontopathogenic bacteria include
gram-negative bacteria such as Aggregatibacter actinomy-
cetemcomitans, Porphyromonas gingivalis and Tannerella
forsythia (75, 76). These bacteria are thought be able to
enter the bloodstream through infected periodontia (77),
have been found in atheromatous plaques (78), amniotic
fluid of pregnant women (79) and are thought to initiate
rheumatoid arthritis in susceptible individuals (80).
Similarly, initial evidence suggests the existence of an
inflammatory reaction triggered by periodontopathogenic
bacteria and inducing systemic inflammatory products
which stimulate the production of beta amyloid and tau
protein in brain tissue leading to Alzheimer’s neuropathol-
ogy (81, 82). Our group and others have shown in recent
years that specific genetic variants affecting the inflam-
matory response (e.g. IL-1 and IL-6 genes) are associated
with detection of periodontopathogenic bacteria (such
as A. actinomycetemcomitans and P. gingivalis) below
the gingival margin (42, 8385). A recent study using a
genome-wide approach in 1,020 subjects (45) identified a
moderate association between locus 1q42 and period-
ontopathogenic bacteria (belonging to the so-called ‘red
complex’) in sub-gingival pockets and confirmed a mod-
erate association our group previously reported between
IL6 genetic variants and presence of pathogenic bacteria
sub-gingivally (42). This adds to the evidence suggesting
that periodontal ‘dysbiosis’ or a shift towards a more
pathogenic microbiota (including pathogenic bacteria
which grow well in inflamed environments, such as
A. actinomycetemcomitans) may be due to specific genetic
variants in the host (86).
Genetic dysbiosis in BV
BV is the most common cause of abnormal vaginal
discharge in women of child-bearing age. The prevalence
in the population is around 1020% (87). The aetiology
of BV is complex. Although it is not classified as a sex-
ually transmitted infection (STI), unprotected vaginal
sex, change of sex partner, STIs, intrauterine devices
and Afro-Caribbean ethnicity are considered risk factors
(24). BV is more common around menstruation and
has been observed in women with pelvic inflammatory
disease (PID). Recurrent BV is common and could lead
to psychological distress and to complications such
as miscarriage and preterm birth, endometritis and PID
in women after an elective termination of pregnancy and
post-hysterectomy infections (88, 89). The microbial
composition of the vaginal biofilm is thought to be
modulated by oestrogen levels, environmental and beha-
vioural factors as well as by host genetic predispositions
(88, 90, 91). In most human populations, the healthy
vagina is mainly populated by Lactobacillus species, which
have a symbiotic relationship with their female host.
Under the influence of female reproductive hormones,
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the vaginal epithelia lead to the production of glycogen
that is metabolised by the lactobacilli leading to lactic acid
production, which is largely responsible for the normal
acidic vaginal pH ofB4.5. Both increasing acidity and the
production of antimicrobials (such as bacteriocins and
hydrogen peroxide) by different lactobacilli species are
associated with greater inhibition of growth of potential
pathogens, such as Gardnerella vaginalis, Prevotella bivia,
Mobiluncus spp. and Group B Streptococcus (92). Lacto-
bacilli may also competitively exclude pathogens by sheer
load or through formation of hostile biofilms. In BV there
is a decrease in lactobacilli load and in the vaginal acidity,
associated with an overgrowth of vaginal anaerobes.
Bacterial species associated with BV include G. vaginalis,
Mycoplasma hominis, Mobiluncus species, Prevotella species,
Leptotrichia sanguinegens/amnionii and Atopobium vaginae
(93). Clinically, BV is diagnosed by the presence of a thin
white, homogeneous discharge coating the vaginal walls
(asymptomatic in about 50% of the cases), with a lack
of inflammation. The vaginal pH in BV is above 4.5.
A clinical diagnosis of BV can be confirmed by performing
microscopy on a gram-stained vaginal smear. The smear is
interpreted in dedicated sexual health clinics by specific
scoring systems such as Nugent’s, based on the mor-
phological appearance of bacteria that are present, or
Hay/Ison criteria, based on abundance of lactobacilli, as
recommended by the Bacterial Special Interest Group
of the British Association for Sexual Health and HIV.
Genetic factors affecting microbial recognition have been
implicated in the predisposition to the carriage of organ-
isms associated with BVand the host immunity may be key
to why some women who are affected by BV have recurrent
or relapsing infections and complications whilst others
do not (44). TLRs are expressed by the cervico-vaginal
epithelia and help initiate the innate response. Genetic
polymorphisms in genes encoding bacterial receptors such
as TLR and inflammatory mediators such as IL-1 receptor
antagonist (IL-1RA) and tumour necrosis factor (TNF)-a
may account for differences in BV and complications
between women (91). Therefore, BV could be considered a
dysbiosis, where genetic factors affecting bacterial recog-
nition and host response may predispose to a shift in the
vaginal microbial biofilm, predisposing to disease initia-
tion. However, as for PS, further evidence to support this
hypothesis is needed.
Similarities between chronic diseases linked with
genetic dysbiosis
The diseases hypothesized as ‘genetic dysbioses’ in this
review (IBD, PS, periodontitis and BV) share a substantial
pathogenic similarity (see Fig. 1), being immune-mediated
diseases due to an imbalance between the integrity of
barrier organs and their colonising microorganisms. The
common underlying mechanism involves the presence of
triggering microbial events acting on a genetically suscep-
tible individual, in the presence of predisposing environ-
mental factors. The epithelia of barrier organs such as
skin, oral cavity, gastrointestinal tract and oro-genital
mucosa act as a mechanical barrier and as a first line
of host defence against invading pathogens, recognising
microorganisms and producing cytokines and antimicro-
bial peptides. These functions give these epithelia the
ability to regulate the normal hostmicrobial homeostasis,
Fig. 1. Schematic representation of potential pathogenic pathways of genetic dysbioses.
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with a key role in the dysbiosis process (94) and allow them
to be physiologically colonised by a number of opportu-
nistic bacteria, which have the potential to cause disease.
Epidemiological surveys have recently suggested a cer-
tain overlap between the conditions that are the object of
this review. The presence of UC has been associated with
periodontitis in a case-control study in Brazil (29). A large
epidemiological study in Taiwan has shown an association
between the presence of periodontitis and the incidence of
PS (95). Furthermore, PS has been shown to increase in
prevalence in subjects affected by CD (96). Gingivitis has
been shown to have a higher prevalence in women affected
by BV compared to women with healthy vaginas (97) and
similar health behaviours and socioeconomic risk factors
have been detected between the two conditions (30). For
PD, BV, IBD and PS, genetic variants with a modifying
effect on disease predisposition involve microbial recogni-
tion and inflammatory pathways, as mentioned above. For
example, TLR-4 genes have been implicated in BV, PD and
IBD pathogenesis (98100). Cytokine-producing genes
such as IL-1b and IL-1RA have been involved in the
pathogenesis of BV, PD, IBD and PS (43, 101104). Levels
of pro-inflammatory cytokines such as TNF-a are in-
creased in CD, PD and PS (27, 105, 106). Among other
functional genes important in the barrier organmicrobe
homeostasis, NLR (nucleotide-binding domain and leucine-
rich repeat containing) genes, encoding mediators of
innate immunity and providing the first line of defence
against pathogens, may provide a link between these
diseases (94). Despite some shared similarities from an
aetio-pathogenic standpoint, differences exist in the devel-
opment of immune response in these conditions, for
example mainly T-lymphocyte mediated for IBD, and
more B-cell dependent in periodontitis (34).
A very intriguing aspect of these genetic dysbioses
is the potential co-morbidities. For example, a preva-
lently anaerobic bacterial environment is associated with
both PD and BV. In a recent study in women with BV
and gingivitis, the vaginal samples had higher counts
of bacteria commonly associated with periodontal dis-
ease such as A. actinomycetemcomitans, P. gingivalis, T.
forsythia and Prevotella intermedia, in comparison with
those with BV but not gingivitis, suggesting that oral
diseases may exacerbate the level of bacterial perturba-
tions associated with BV (97). In periodontitis, the
ulceration of the pocket epithelium results in migration
of periodontal microbes into the bloodstream, even during
chewing and tooth brushing (77, 107, 108). The survival of
these bacteria in the systemic circulation and their final
destiny are still unclear. Interestingly, initial evidence
showed that out of 50 human specimens obtained during
carotid endarterectomy analysed by PCR, 44% of ather-
omas were found positive for at least one periodontal
pathogen (78). Oral pathogens have also been linked with a
role in prematurity via haematogenous route (109, 110)
and with pregnancy complications (111). It is hypothe-
sized that oral pathogens can spread to the vaginal cavity
within the female host via the gastrointestinal tract or by
transmission between individuals via oro-genital contact
(110). A rate of physiological bacterial translocation is
thought to occur in the human gut, by the intra-epithelial
route and then via the mesenteric lymph nodes (or
directly to the portal circulation in case of damage to the
epithelium) (112, 113). Translocation of indigenous gut
microbiota or microbial elements has also been shown
in an animal model of sepsis (114) and, in HIV infection,
is a major mechanism contributing to generalised immune
activation and subsequent disease progression. This is
in line with the theory that one of these genetic dysbioses
might alter the biodiversity of the microbiota provok-
ing a loss of immunological tolerance to commensal
bacteria, hence predisposing to other diseases in the
body (94).
Summary and conclusions
This review introduces the concept of genetic dysbiosis,
to indicate a host genetically driven deviation from the
normal composition of human tissue-distinct microbial
biofilms. Inflammatory diseases such as IBD, PS, peri-
odontitis and BV are likely to be initiated through this
mechanism. The strongest evidence comes from studies
on CD and on periodontitis, showing alterations in the
normal microbiota dependent on specific host genetic
variants (45, 57). An additional pathogenic mechanism for
these conditions is represented by a host genome-driven
misrecognition of the normal microbiota, which might over-
lap or in some cases represent a different disease-initiating
pathway. Bacterial translocation, protein citrullination
and loss of immunological tolerance are mechanisms
through which one of these dysbioses could influence and
potentially trigger another. Therefore, although the dif-
ferent epithelial and mucosal surfaces of the body have
their own distinct microbiotas with little overlap between
species in health (9), this may change in the presence of a
genetically-driven dysbiosis. Large studies investigating
host genetic variants and microbiome analyses in different
body locations may substantiate the hypotheses reported
here, elucidate the pathogenic process and potentially
provide new weapons (such as for example diet or
probiotics) in the treating physicians’ prevention and
treatment arsenal.
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